Center for Substance Abuse Treatment; Notice of Meeting Cancellation, 1181 [2019-00545]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 22 / Friday, February 1, 2019 / Notices
Dated: January 28, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–00640 Filed 1–31–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Center for Substance Abuse
Treatment; Notice of Meeting
Cancellation
This is a notice of meeting
cancellation of the Substance Abuse and
Mental Health Services
Administration’s (SAMHSA) Center for
Substance Abuse Treatment (CSAT)
National Advisory Council (NAC) of
February 27, 2019, 9:00 a.m.–5:00 p.m.
(EDT). The meeting was announced on
the Federal Register/Vol. 83, No. 245/
Friday, December 21, 2018/[FR Doc.
2018–27637 Filed 12–20–18].
Future meetings will be announced at
a later time. Pertinent council
information may be obtained by
contacting the CSAT National Advisory
Council Designated Federal Officer;
Tracy Goss (see contact information
below).
Council Name: SAMHSA’s Center for
Substance Abuse Treatment, National
Advisory Council.
Contact: Tracy Goss, Designated
Federal Officer, CSAT National
Advisory Council, 5600 Fishers Lane,
Rockville, Maryland 20857 (mail),
Telephone: (240) 276–0759, Fax: (240)
276–2252, Email: tracy.goss@
samhsa.hhs.gov.
Dated: January 28, 2019.
Carlos Castillo,
Committee Management Officer.
[FR Doc. 2019–00545 Filed 1–31–19; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
VerDate Sep<11>2014
21:23 Jan 31, 2019
Jkt 247001
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
SUMMARY:
PO 00000
Frm 00135
Fmt 4703
Sfmt 4703
1181
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated January 23, 2017 (82
FR 7920), the following HHS-certified
laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
844–486–9226
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center—Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Cordant Health Solutions, 2617 East L
Street, Tacoma, WA 98421, 800–442–
0438, (Formerly: STERLING Reference
Laboratories)
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 84, Number 22 (Friday, February 1, 2019)]
[Notices]
[Page 1181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-00545]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment; Notice of Meeting
Cancellation
This is a notice of meeting cancellation of the Substance Abuse and
Mental Health Services Administration's (SAMHSA) Center for Substance
Abuse Treatment (CSAT) National Advisory Council (NAC) of February 27,
2019, 9:00 a.m.-5:00 p.m. (EDT). The meeting was announced on the
Federal Register/Vol. 83, No. 245/Friday, December 21, 2018/[FR Doc.
2018-27637 Filed 12-20-18].
Future meetings will be announced at a later time. Pertinent
council information may be obtained by contacting the CSAT National
Advisory Council Designated Federal Officer; Tracy Goss (see contact
information below).
Council Name: SAMHSA's Center for Substance Abuse Treatment,
National Advisory Council.
Contact: Tracy Goss, Designated Federal Officer, CSAT National
Advisory Council, 5600 Fishers Lane, Rockville, Maryland 20857 (mail),
Telephone: (240) 276-0759, Fax: (240) 276-2252, Email:
tracy.goss@samhsa.hhs.gov.
Dated: January 28, 2019.
Carlos Castillo,
Committee Management Officer.
[FR Doc. 2019-00545 Filed 1-31-19; 8:45 am]
BILLING CODE 4162-20-P
